The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. The study team aims to assess the prevalence of circulating IgG antibodies to SARS-CoV-2 and the factors associated with sero-prevalence. These data will be used to estimate the total population that has been exposed to the virus (asymptomatic and symptomatic), the proportion of the population that may be protected by natural immunity, and the proportion that is susceptible. Data obtained from this research will be shared with the Florida Department of Health.
Study Type
OBSERVATIONAL
Enrollment
1,135
10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
A Weck-cel swab will be used to collect secretions from the mucosal epithelium
A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Moffitt Cancer Center
Tampa, Florida, United States
Percentage of Participants who test positive for SARS-CoV-2 antibodies at first visit
All participants who respond to study invitation letter will be tested for SARS-CoV-2 antibodies after completing a web-based questionnaire.
Time frame: At study start
Percentage of Participants who test positive for SARS-CoV-2 antibodies at second visit
Participants who tested positive for SARS-CoV-2 antibodies at first study visit will be tested for antibodies to SARS-CoV-2 again at 4 weeks.
Time frame: At 4 weeks
Percentage of Participants who test positive for SARS-CoV-2 antibodies at third visit
Participants who tested positive for SARS-CoV-2 antibodies at second study visit will be tested for antibodies to SARS-CoV-2 again at 3 months.
Time frame: At 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.